Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

0(0%)

Results Posted

67%(4 trials)

Phase Distribution

Ph phase_2

14%

Ph phase_4

57%

Ph phase_3

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 2Efficacy & side effects

1(16.7%)

Phase 3Large-scale testing

1(16.7%)

Phase 4Post-market surveillance

4(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(6)

Detailed Status

Completed6

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (16.7%)

Phase 31 (16.7%)

Phase 44 (66.7%)

Trials by Status

completed686%

not_yet_recruiting114%

Recent Activity

0 active trials

Showing 5 of 7

not_yet_recruitingphase_4

Clinical Trials (7)

Showing 7 of 7 trials

NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting

NCT03832010Phase 4

Steroid-reducing Effects of Crisaborole

Completed

NCT03770858

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Completed

NCT03645057Phase 3

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

Completed

NCT04023084Phase 4

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Completed

NCT03567980Phase 4

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

Completed

NCT03351114Phase 2

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7